Q-CHECK Pharmaceuticals

What Q-CHECK Pharmaceuticals does

Q-Check Pharmaceuticals Pvt. Ltd. is a privately held Indian pharmaceutical company founded in 2004 in Chennai, Tamil Nadu, by Mr. K. Pradhip Kumar (Chairman) and Mr. C. Kathiravan (Managing Director), with Dr. Madanagopal serving as Executive Director. The company manufactures and distributes branded pharmaceutical formulations across seven therapy areas — Diabetes Management, Cardiac Care, Neuro/Psychiatry, Women's Health, Orthopaedics, Nutrition, and General Health — through a portfolio of more than 50 products in oral, injectable, syrup, drop, and oral spray dosage forms. Its technology base is centred on conventional pharmaceutical formulations with WHO-GMP and ISO 9001:2015 certified quality standards, and the most notable technical differentiation is HydroCheck Oral Spray (50ml), launched in 2024 and positioned as India's first oral spray for xerostomia.

The company operates a field-sales-led B2B model organised into three specialist divisions — Space (hospital and specialty care, covering neurologists, psychiatrists, and neuropsychiatrists), Stream (chronic and lifestyle disease management through retail pharmacies and general practitioners), and Proxima (women's health and orthopaedics) — each with dedicated medical representatives and distinct go-to-market focus. Its marketed customers include hospital chains such as Apollo Hospitals Chennai, and the distribution footprint covers every state in India, with publicly stated ambitions for overseas markets and new manufacturing facilities. Pricing is not publicly disclosed; the company operates through standard pharmaceutical prescription-driven B2B channels (hospitals, specialty care, retail pharmacies) governed by Indian pharmaceutical pricing regulations. No institutional investment, patents, AI capabilities, or digital products are indicated in the public record.

Name

Q-CHECK Pharmaceuticals

Legal name

Q-Check Pharmaceuticals Pvt. Ltd.

Website

https://qcheckpharma.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

51–100 employees

Short description

Q-Check Pharmaceuticals is a privately held Indian pharma company founded in 2004 that manufactures and distributes branded generic formulations across 7 therapy areas — diabetes, cardiac, neuro, women's health, orthopaedics, nutrition, and general health — through a pan-India field-sales network of 50+ products organised into three specialist divisions serving hospitals, retail pharmacies, and specialist physicians.

Ownership category

akta.pro rank

Product category

Branded Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industries

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

Keywords

• Pharmaceutical formulations
• Cardio-diabetic medications
• Neuro-psychiatric drugs
• Women's health supplements
• Ortho musculoskeletal therapies

Headquarters

HQ city

Chennai

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Operations, Supply Chain, Personnel, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Q-Check generates revenue through the sale of branded pharmaceutical formulations across 7 therapy areas. The company operates three specialist divisions (Space, Stream, Proxima) each serving distinct market segments — hospital/specialty, chronic care retail, and women's health/orthopaedics — with products distributed pan-India to doctors, hospitals, and retail pharmacies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels2 records

Core offering

Q-Check Pharmaceuticals develops, manufactures, and distributes branded pharmaceutical formulations across 7 therapy areas (Diabetes Management, Cardiac Care, Neuro/Psychiatry, Women's Health, Orthopaedics, Nutrition, and General Health) via three specialist divisions — Space, Stream, and Proxima. The company markets 50+ products in multiple dosage forms (tablets, capsules, syrups, drops, injections, oral sprays) to doctors, hospitals, and retail pharmacies across India, with notable first-to-market innovation in HydroCheck Oral Spray for xerostomia.

Product overview

Q-Check Pharmaceuticals operates as a pan-India pharmaceutical company with three specialist divisions — Space Division (hospital and specialty care), Stream Division (chronic and lifestyle care), and Proxima Division (women's health and orthopaedics). The company offers a portfolio of 52+ pharmaceutical products across 7 therapy areas: Diabetes Management (12 products including flagship HydroCheck), Cardiac Care (7 products including flagship Monascus), Neuro Care (6 products including flagship Dobinoid), Women's Health (7 products), Orthopaedics (4 products including flagship NexJoint), Nutrition (8 products including flagship Alphamix), and General Health (7 products including flagship Meljio and X-Biotic). The portfolio includes branded generics, injectable nutritional supplements, and specialty formulations designed for retail pharmacies, hospitals, and healthcare providers across India.

Differentiator

Problem solved

Functional benefit

Products and services

• Alphamix Flagship nutritional supplement for therapeutic nutrition and micronutrient replenishment in the Nutrition therapy area.
• Dobinoid Flagship neurological and psychiatric formulation for epilepsy, depression, anxiety, and neuropathic pain management.
• HydroCheck India's first oral spray for xerostomia (dry mouth), delivering instant moisture relief in a 50ml format. First-of-its-kind in the Indian market with no equivalent alternatives.
• Meljio Flagship general health product for broad-spectrum solutions covering infections, immunity, fever management, vitamins, and wellness.
• Monascus Flagship cardiovascular formulation for evidence-based therapies covering hypertension, heart failure, dyslipidemia, and anticoagulation management.
• NexJoint Flagship orthopaedic formulation targeting joint health, bone density, pain management, and post-surgical recovery.
• X-Biotic Flagship general health antibiotic therapy for bacterial infections and anti-infective treatment.
• Alphamix BT Nutritional supplement variant for therapeutic nutrition.
• Alphamix Inj Injectable nutritional supplement for therapeutic nutrition and micronutrient replenishment.
• Atloma Cardiac care product for cardiovascular therapies.
• Avascare Cardiac care product for cardiovascular disease management.
• Azidraw General health anti-infective product for bacterial infections.
• Ben Q Met Diabetes management product for blood glucose control.
• Betbanc Drops Nutritional supplement in drop form for iron deficiency and anaemia.
• Betbanc Drops Jr Paediatric nutritional supplement in drop form for iron deficiency in children.
• Betbanc Syrup Nutritional syrup supplement for iron deficiency anaemia.
• Betbanc+ Nutritional supplement with enhanced formulation for micronutrient replenishment.
• BHT Neuro care product for neurological and psychiatric conditions.
• Bilvocit M General health product for hepatic support and related conditions.
• Brinergy Women's health product supporting hormonal wellness and reproductive health.
• Calgrel D3 Orthopaedic product for calcium deficiency, bone density, and musculoskeletal care.
• Curefix General health product for wound healing and recovery.
• Dapacheck Diabetes management product for blood glucose management.
• Emfertol Women's health product for fertility support and reproductive health.
• Emphacare Diabetes management product for blood glucose control.
• Fidafol Women's health product for folic acid supplementation and prenatal care.
• Finfer Women's health iron supplement for iron deficiency anaemia.
• Finfer FCM Women's health iron supplement with ferric carboxymaltose for iron deficiency anaemia.
• Gabacheck Neuro care product for neuropathic pain management.
• Gliclafin Diabetes management product for blood glucose control.
• Glimcare Diabetes management product for blood glucose management.
• Lanspure Jr Paediatric product for gastric disorders and acid reflux in children.
• Let O Fix Women's health product for hormonal imbalance and menopausal support.
• LinaQ Diabetes management product for blood glucose control.
• Metofin Cardiac care product for cardiovascular therapies.
• Pantofin General health product for acid reflux and GERD management.
• Prechoice Neuro care product for psychiatric conditions.
• Q Repa Diabetes management product for blood glucose control.
• Q Spin Cardiac care product for cardiovascular disease management.
• Rabacheck General health product for gastric disorders and acid reflux.
• RV Cardiac care product for cardiovascular therapies.
• RV Gold Cardiac care product for enhanced cardiovascular support.
• Sitacare Diabetes management product for DPP-4 inhibitor therapy.
• Tenlicare Diabetes management product for blood glucose control.
• Titrate Orthopaedic product for joint health and pain management.
• Titrate D Orthopaedic product with vitamin D for bone health and pain management.
• Ursi UTI Women's health product for recurrent urinary tract infection management.
• Varisil Neuro care product for neurological conditions.
• Vildacare Diabetes management product for blood glucose control.
• Vitagrams Nutritional supplement as vitamin complexes for general wellness.
• Voglifin Diabetes management product for blood glucose control.
• Zolgo Neuro care product for neurological conditions.

Quantifiable outcome

• HydroCheck is India's first oral spray for xerostomia — first-of-its-kind in the Indian market

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators6 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Ipca Laboratories: Indian mid-size pharma with branded generics across cardiac, anti-infectives and pain management — comparable mid-market positioning to Q-Check, with similar reliance on pan-India retail pharmacy distribution.
• Mankind Pharma: One of India's largest branded-generic pharma companies with a deep chronic-care portfolio in diabetes, cardiac and women's health — directly comparable therapeutic mix and field-sales-led distribution model to Q-Check across the same Indian retail-pharmacy and hospital channels.
• Torrent Pharmaceuticals: Indian pharma company with a flagship chronic-care portfolio in cardiology, diabetes and CNS — directly mirrors Q-Check's cardiometabolic and neuro focus, with comparable field-sales reach to GPs and specialists.
• Glenmark Pharmaceuticals: India-headquartered branded pharma with a broad chronic-care portfolio (cardiac, diabetes, respiratory, dermatology) and significant international presence — comparable multi-therapy Indian pharma with branded-generic orientation.
• Alkem Laboratories: Indian multi-therapy branded pharma with strong presence in anti-infectives, cardiology, diabetes and neuro — directly overlaps Q-Check's therapy areas and operates a similar pan-India field-sales model targeting GPs and specialists.
• Macleods Pharmaceuticals: Privately held Indian pharma with a broad branded-generic portfolio spanning anti-infectives, cardiac, diabetes and women's health — closely matches Q-Check's founder-led, multi-therapy, pan-India branded-pharma profile.
• Intas Pharmaceuticals: Large Indian branded-generic and specialty pharma with diversified therapy-area coverage including cardiac, neuro, women's health and oncology — same horizontal branded-pharma strategy and pan-India distribution footprint as Q-Check.
• Ajanta Pharma: Indian branded pharma with strong chronic-disease portfolio across cardiac, diabetes and dermatology, exporting to semi-regulated markets — same therapy breadth, Indian market focus and emerging international ambitions as Q-Check.
• Eris Lifesciences: Indian mid-cap pharma focused on chronic-care categories including diabetes, cardiac, women's health and neuro — directly comparable to Q-Check's Stream and Proxima divisions in therapy focus and GP/specialist channel mix.

Broad incumbents

• Zydus Lifesciences (Cadila): One of India's largest integrated pharma companies with broad branded-generic and specialty portfolios covering cardiac, diabetes, women's health, neuro and gastroenterology — overlaps significantly with Q-Check's therapy areas but at a much larger scale and with greater manufacturing and R&D infrastructure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/qcheckpharma
• LinkedInlinkedin.com/company/q-check

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Q-CHECK Pharmaceuticals